These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 10082659)

  • 1. Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis.
    Okada M; Matsumori A; Ono K; Miyamoto T; Takahashi M; Sasayama S
    Biochem Biophys Res Commun; 1999 Feb; 255(1):80-7. PubMed ID: 10082659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
    Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
    Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity.
    Robak E; Woźniacka A; Sysa-Jedrzejowska A; Stepień H; Robak T
    Eur Cytokine Netw; 2001; 12(3):445-52. PubMed ID: 11566625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model.
    Nakabayashi M; Morishita R; Nakagami H; Kuba K; Matsumoto K; Nakamura T; Tano Y; Kaneda Y
    Diabetologia; 2003 Jan; 46(1):115-23. PubMed ID: 12637990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients.
    Salgado R; Vermeulen PB; Benoy I; Weytjens R; Huget P; Van Marck E; Dirix LY
    Br J Cancer; 1999 May; 80(5-6):892-7. PubMed ID: 10360671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells.
    Jiang WG; Hiscox SE; Parr C; Martin TA; Matsumoto K; Nakamura T; Mansel RE
    Clin Cancer Res; 1999 Nov; 5(11):3695-703. PubMed ID: 10589789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?
    Tabone MD; Landman-Parker J; Arcil B; Coudert MC; Gerota I; Benbunan M; Leverger G; Dosquet C
    Clin Cancer Res; 2001 Mar; 7(3):538-43. PubMed ID: 11297245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF.
    Jia H; Jezequel S; Löhr M; Shaikh S; Davis D; Soker S; Selwood D; Zachary I
    Biochem Biophys Res Commun; 2001 Apr; 283(1):164-73. PubMed ID: 11322784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kringle 1-4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells.
    Kuba K; Matsumoto K; Ohnishi K; Shiratsuchi T; Tanaka M; Nakamura T
    Biochem Biophys Res Commun; 2000 Dec; 279(3):846-52. PubMed ID: 11162438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin-binding angiogenic factors (basic fibroblast growth factor and vascular endothelial growth factor) in early neonatal life.
    Malamitsi-Puchner A; Tziotis J; Protonotariou E; Xyni K; Sarandakou A; Creatsas G
    Pediatr Res; 1999 Jun; 45(6):877-80. PubMed ID: 10367782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis.
    Jia H; Lohr M; Jezequel S; Davis D; Shaikh S; Selwood D; Zachary I
    Biochem Biophys Res Commun; 2001 May; 283(2):469-79. PubMed ID: 11327725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocyte growth factor stimulated angiogenesis without inflammation: differential actions between hepatocyte growth factor, vascular endothelial growth factor and basic fibroblast growth factor.
    Kaga T; Kawano H; Sakaguchi M; Nakazawa T; Taniyama Y; Morishita R
    Vascul Pharmacol; 2012 Aug; 57(1):3-9. PubMed ID: 22361334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
    Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
    Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts.
    Rofstad EK; Halsør EF
    Cancer Res; 2000 Sep; 60(17):4932-8. PubMed ID: 10987309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human three-dimensional fibroblast cultures express angiogenic activity.
    Pinney E; Liu K; Sheeman B; Mansbridge J
    J Cell Physiol; 2000 Apr; 183(1):74-82. PubMed ID: 10699968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
    Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
    Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
    Aguayo A; Kantarjian HM; Estey EH; Giles FJ; Verstovsek S; Manshouri T; Gidel C; O'Brien S; Keating MJ; Albitar M
    Cancer; 2002 Nov; 95(9):1923-30. PubMed ID: 12404286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenic factors: vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) are not necessarily elevated in patients with advanced renal cell carcinoma.
    Edgren M; Lennernäs B; Larsson A; Kälkner KM
    Anticancer Res; 2001; 21(2B):1423-9. PubMed ID: 11396226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.